Improved Endpoints for Cancer Immunotherapy Trials

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Developing Immunotherapy As Legitimate Therapy for Patients With Prostate Cancer

(2010) Eric J. Small et al.   JOURNAL OF CLINICAL ONCOLOGY

Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium

(2009) Cedrik Michael Britten et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells

(2009) Sylvia Janetzki et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

(2009) J. Weber et al.   CLINICAL CANCER RESEARCH

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Improving the efficacy of cancer immunotherapy

(2009) J. Copier et al.   EUROPEAN JOURNAL OF CANCER

“MIATA”—Minimal Information about T Cell Assays

(2009) Sylvia Janetzki et al.   IMMUNITY

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

(2009) Jedd D Wolchok et al.   LANCET ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group

(2008) Alessandro Testori et al.   JOURNAL OF CLINICAL ONCOLOGY

New Response Criteria Proposed for Immunotherapies

(2008) Rabiya S. Tuma   JNCI-Journal of the National Cancer Institute

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

(2008) Christopher Wood et al.   LANCET

Cancer Immunology

(2008) Olivera J. Finn   NEW ENGLAND JOURNAL OF MEDICINE

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

(2008) F. S. Hodi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS

(2008) F Stephen Hodi et al.   Nature clinical practice. Oncology